Neptune's Customer is Awarded "Product of the Year 2011" in Denmark
September 28 2011 - 9:00AM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX-V:NTB) is proud to announce that
Omnikrill (100% Pure NKO®) has been awarded as the Product of the
Year in Denmark. Complimented among other things for its innovative
profile, Omnikrill is a product commercialized by Biosym, a client
of Neptune.
This great honour was granted to Biosym on September 17th during
the largest health fair in Denmark (Helsam A/S). Amongst many
nutraceutical products, Omnikrill distinguished itself as best
product of the year.
Health food store retailers in Denmark voted anonymously and
described the winning product as:
Innovative and ground-breaking – Supreme quality –
Beneficial effect – Consideration for the environment – Highest
content of active ingredients
Biosym is one of the TOP 10 Dietary supplement selling brands in
Denmark. Omnikrill was first introduced to the Danish market in
2009 and following its great success, the company decided to
introduce it in Sweden in 2011.
"I would like to congratulate Neptune –since we could not have
done this without their strong commitment to science and research,
as well as the superior quality of NKO®, and their support whenever
needed," stated Kim Nielsen, CEO of Biosym Danmark.
Biosym intends to commercially use this award in the upcoming
months, an excellent exposure that NKO® will certainly benefit
from.
Neptune is committed to supporting its partners in the
development of new markets. "Our scientific, legal and marketing
teams are working together toward educating the industry and
consumers about this new generation of Omega-3s, its health
benefits and promising future. This award is well-deserved and
confirms our conviction in NKO's potency," stated Caroline
Gauthier, Marketing Manager at Neptune Technologies &
Bioressources.
NKO® was also acknowledged in June of 2010 as the best product
in Belgium during the 11th Congress of "Nutrition & Santé."
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024